UK markets close in 3 hours 53 minutes
  • FTSE 100

    7,067.09
    +34.24 (+0.49%)
     
  • FTSE 250

    22,331.42
    +117.28 (+0.53%)
     
  • AIM

    1,238.05
    +3.96 (+0.32%)
     
  • GBP/EUR

    1.1621
    -0.0008 (-0.07%)
     
  • GBP/USD

    1.4198
    +0.0060 (+0.43%)
     
  • BTC-GBP

    32,103.46
    +92.10 (+0.29%)
     
  • CMC Crypto 200

    1,268.75
    +70.84 (+5.91%)
     
  • S&P 500

    4,163.29
    -10.56 (-0.25%)
     
  • DOW

    34,327.79
    -54.34 (-0.16%)
     
  • CRUDE OIL

    66.37
    +0.10 (+0.15%)
     
  • GOLD FUTURES

    1,867.20
    -0.40 (-0.02%)
     
  • NIKKEI 225

    28,406.84
    +582.01 (+2.09%)
     
  • HANG SENG

    28,593.81
    +399.72 (+1.42%)
     
  • DAX

    15,442.94
    +46.32 (+0.30%)
     
  • CAC 40

    6,380.12
    +12.77 (+0.20%)
     

Novo Nordisk A/S – Share repurchase programme

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Novo Nordisk A/S
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Bagsværd, Denmark, 26 April 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 3 February 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 3 February 2021 to 3 May 2021.

Since the announcement as of 19 April 2021, the following transactions have been made:

Number of
B shares

Average
purchase price

Transaction
value, DKK

Accumulated, last announcement

5,647,277

2,495,309,191

19 April 2021

115,000

450.52

51,809,636

20 April 2021

115,000

450.58

51,816,260

21 April 2021

115,000

456.69

52,519,913

22 April 2021

110,000

459.93

50,592,657

23 April 2021

110,000

456.72

50,239,444

Accumulated under the programme

6,212,277

2,752,287,101

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 45,114,889 B shares of DKK 0.20 as treasury shares, corresponding to 1.9% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 3 February 2021. As of 23 April 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 6,212,277 B shares at an average share price of DKK 443.04 per B share equal to a transaction value of DKK 2,752,287,101.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:

Anne Margrethe Hauge

+45 3079 3450

amhg@novonordisk.com

Michael Bachner (US)

+1 609 664 7308

mzyb@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Valdemar Borum Svarrer

+45 3079 0301

jvls@novonordisk.com

Ann Søndermølle Rendbæk

+45 3075 2253

arnd@novonordisk.com

Mark Joseph Root

+45 3079 4211

mjhr@novonordisk.com

Kristoffer Due Berg (US)

+1 609 235 2989

krdb@novonordisk.com

Company announcement No. 26 /2021

Attachment